Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03247530 · ClinicalTrials.gov registry record · Phase 3
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
A Phase 3 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 477
- Enrollment target
NCT03247530 is a Phase 3 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 477 participants.
The verdict
NCT03247530, a Phase 3 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 477 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of low doses of SPN-812 in children 6-11 years of age diagnosed with ADHD.
Interventions
- DRUG Placebo
- DRUG 100mg SPN-812
- DRUG 200mg SPN-812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2018-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03247530
The ClinicalTrials.gov registry entry for NCT03247530 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 477 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03247530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03247530 about?
NCT03247530 is a clinical study titled "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD". This study will evaluate the efficacy and safety of low doses of SPN-812 in children 6-11 years of age diagnosed with ADHD.
What is the current status of trial NCT03247530?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 477 participants. The study started on 2017-10-20. Estimated completion is 2018-09-12.
What interventions are being tested in trial NCT03247530?
The interventions under investigation include: Placebo (DRUG), 100mg SPN-812 (DRUG), 200mg SPN-812 (DRUG).
Who is sponsoring clinical trial NCT03247530?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.